Inspire’s Post

On Adverse Drug Events Awareness Day, March 24th, Simplify Genomics supports the efforts to incorporate pharmacogenomic testing into standard patient care. According to the American Society of Pharmacovigilance, adverse drug events represent one million emergency department visits, 2.2 million hospital admissions, 3.5 million physician office visits, and $136 billion in U.S. healthcare costs yearly. The estimated number of annual ADE deaths is 100,000+, placing it as the 4th leading cause of death for Americans. #fourthcause #pharmacogenomics

Testing the effectiveness of a drug on a disease can be quite challenging, especially when the disease's natural history involves many patients improving on their own. For example, in conditions like COVID where the majority of people recover without intervention, it's difficult to determine whether a patient's improvement is due to the medication or just the natural course of the illness. On the other hand, with a disease like Castleman, where no one improves without treatment, it's much easier to attribute a patient's recovery directly to the drug. This contrast highlights the complexities of clinical trials—where sometimes, a drug's true impact might be masked by the body's natural healing process. Determining whether a medication genuinely works requires careful analysis and often, comparing results to placebos, which can sometimes show a surprisingly high rate of recovery on their own. At Every Cure, we aim to navigate these complexities by employing innovative approaches to drug repurposing and clinical trials. Our goal is to identify existing medications that might be effective against diseases with unclear treatment paths. By leveraging artificial intelligence and comprehensive data analysis, we can better predict which drugs have the highest potential to make a difference. This allows us to prioritize clinical trials for drugs that could offer real benefits to patients, even in cases where the disease's natural history makes it challenging to assess a drug's effectiveness. Ultimately, we strive to bring life-saving treatments to patients faster, ensuring no opportunity for healing is overlooked. #DrugRepurposing #EveryCure #RareDisease #Pharma #HealthcareInnovation

Alzheimer’s disease is more than just a medical condition; it’s a profound challenge that affects over 50 million lives globally. As we strive to advance in our professional and personal lives, it’s crucial to raise awareness and support for those impacted by this debilitating illness. I was interested to read this recent article in #NewScientist about next generation therapies https://lnkd.in/gzBq_iCe

The Medicine Maker feature article - Don’t Forget the Elderly Sharmeen Roy, PharmD, BCPS, Chief Strategy and Science Officer at DoseMe, discusses how across the board, older adults are significantly underrepresented in clinical trials. In fact, they comprise around 25–40 percent of clinical trial participants, despite making up the majority of prescription drug users and having the highest disease burden. Read the full article that dives into pharmacokinetic differences, safety endpoints and efficacy analysis. https://lnkd.in/eUxbabdq #pharmacokinetic #safety #precisiondosing

Survey: Patients Report Improvements, Few Serious Side-effects Following Use Of High-THC Flower

NEW STUDY - Palatal Tremor Following C19 Product Administration Palatal tremor (PT) is a rare movement disorder characterized by rhythmic, usually involuntary, jerky movements of the soft palate. A 20-year-old girl presented with clinical symptoms of PT 2 days after receiving a dose of AstraZeneca. The patient had persistent audible clicks associated with rhythmic contractions of the soft palate. Complete resolution of symptoms occurred 2 days after the administration of oral clonazepam. The authors conclude, "This case is the first to document PT arising after receiving [AstraZeneca]. This finding highlights the necessity of considering PT in the differential diagnosis for patients who develop auditory symptoms following [product administration]." https://lnkd.in/ghdV2Ezg #MFScholar

NEW STUDY - Palatal Tremor Following C19 Product Administration Palatal tremor (PT) is a rare movement disorder characterized by rhythmic, usually involuntary, jerky movements of the soft palate. A 20-year-old girl presented with clinical symptoms of PT 2 days after receiving a dose of AstraZeneca. The patient had persistent audible clicks associated with rhythmic contractions of the soft palate. Complete resolution of symptoms occurred 2 days after the administration of oral clonazepam. The authors conclude, "This case is the first to document PT arising after receiving [AstraZeneca]. This finding highlights the necessity of considering PT in the differential diagnosis for patients who develop auditory symptoms following [product administration]." https://lnkd.in/ghdV2Ezg

Leqembi and Alzheimer’s: What to Know About the New Drug, Treatment and Benefits: As the F.D.A. considers a new Alzheimer’s medication, we asked experts how the rollout of a similar drug has gone. https://lnkd.in/ddqFvq7Y

Use of patient-reported outcomes (PROs) to inform risks and benefits is more common in later than early phase trials. This new Lancet (eClinicalMedicine) article discusses a two-day expert roundtable that stressed the necessity of PRO inclusion in early phase trials. If you are studying one of our 35+ disease areas or need a fit-for-purpose PRO or ObsRO developed by an expert team, get in touch. #HealthIndexes #PatientReportedOutcomes #ClinicalTrialDesign

Chronic Diarrhea International Guidelines - Much less published guidance compared to chronic constipation. It differentiates between the different causes and provides HCP recommendations for the assessment and management. https://lnkd.in/gCbTyZ2S